US FDA advisory committee votes for GSK ’s Shingrix to prevent shingles

The US Food and Drug Administration ’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted unanimously for GlaxoSmithKline’s (GSK) Shingrix (HZ/su) to prevent herpes zoster (shingles) in adults of 50 years of age and a…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news